Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : IMMD - ImmuDyne -- Ignore unavailable to you. Want to Upgrade?

To: PAUL MARTIN who wrote (1183)	5/11/1998 12:57:00 PM
From: Mel Fox	Respond to of 1249

All: Here is news from Yahoo today! This LOOKS LIKE good news, maybe, I think, kindof, etc.. Monday May 11, 8:23 am Eastern Time Company Press Release ImmuDyne Inc. Announces Dismissal of Involuntary Bankruptcy Petition and Dismissal of Nevada Lawsuit HOUSTON--(BW Healthwire)--May 11, 1998--ImmuDyne Inc. (''ImmuDyne'' or the ''Company'') announced that it has successfully defended against a further challenge to certain of its valuable license agreements in gaining the dismissal of an involuntary Chapter 7 bankruptcy petition filed against the Company by Mr. and Mrs. Byron Donzis and Carmel Research Inc.(Carmel). The petition, which was filed in the US Bankruptcy Court in Houston in the Southern District of Texas in December 1997, was dismissed by the Bankruptcy Court when it agreed with the Company's management that the petition was without merit. The Company believes that the petition was a further attempt by Carmel and Donzis to avoid the Summary Judgment Order entered by the 37th judicial Court in San Antonio reaffirming the enforceability of the Company's license agreements with Carmel. These license agreements provide the Company with the exclusive right to use important ingredients in several of the Company's products. As a result of the dismissal of the petition, the Company expects to seek recovery from Carmel and Donzis for the damages, cost, and expenses incurred by the Company as a result of the improper petition. Dr. Leonid Ber, chief operating officer of the Company, stated, ''The management of ImmuDyne has always believed that ImmuDyne was never in a situation that merited the filing of an involuntary bankruptcy petition. This latest series of events further underscores the lengths to which Carmel and Donzis have gone to challenge the valuable rights of the Company. The Company is hopeful that Carmel and Donzis will comply with various court orders and allow the Company to refocus management's efforts from defending meritless legal actions to improving the performance of the Company.'' In a separate matter, the Company announced that a lawsuit filed by Byron A. Donzis and Carmel Research Inc. on December 24, 1997 in the State of Nevada, attempting to circumvent the Summary Judgment Order and prevent ImmuDyne from benefiting from the results thereof, was dismissed on March 31, 1998. Management pointed out that in a span of less than 12 months, Byron A. Donzis and/or Carmel has instituted 7 different legal actions or lawsuits against ImmuDyne. Dr. Leonid Ber, COO, stated ''In spite of all the legal actions filed by Mr. Donzis and related entities, ImmuDyne will remain focused on its number one priority of increasing revenues and profitability, thus enhancing shareholder value.'' ''Safe Harbor'' Statement under the Private Securities Litigation Reform Act of 1995. The statements which are not facts contained in the release are forward-looking statements that involve risks and uncertainties, some of which are outside the Company's control, and accordingly, actual results may differ materially. Factors that might cause such a difference include, but are not limited to,implementation of the Company's strategies, the impact of competitive and industry developments, the results of research and development efforts by the Company, product development by the Company and customer acceptance of the Company's products and services. ImmuDyne is a Texas based company specializing in macrophage technology and immune systems stimulants for cosmetic, human nutritional and aquacultural use. The common stock of ImmuDyne is traded on the OTC Bulletin Board under the symbol IMMD. For investment information, contact the Company at 713/783-7034. Contact: ImmuDyne Inc., Houston 713/783-7034

To: PAUL MARTIN who wrote (1183)	5/11/1998 1:09:00 PM
From: Mel Fox	Read Replies (1) \| Respond to of 1249

All: From Yahoo here is More News ... Earnings! Hmmm, Revenue DOWN ... ... Expenses DOWN ... ... profit UP!!!! Monday May 11, 8:23 am Eastern Time Company Press Release ImmuDyne Inc. Announces Second Quarter Results and Selection of Accounting Firm HOUSTON--(BW HealthWire)--May 11, 1998--ImmuDyne Inc. (''ImmuDyne'' or the ''Company'') announced results for the second quarter ending February 28, 1998. Revenues for the quarter were $486,553, as compared to $607,111 for the quarter ending February 28, 1997. The Company had a net profit of $65,977 for the quarter ending February 28, 1998 compared to a profit of $1,195 for the same period of the prior year. Total operating expenses decreased to $292,621 for the quarter ended 2/28/98, down from $453,754 for the same period last year. Management emphasized the continued path of strong expense control toward building a firmer foundation for the Company. The Company also announced that Mazars and Guerard, LLP, of New York, NY, has been selected as the Company's Certified Public Accountants. The firm is a member of the Securities and Exchange Commission section of the AICPA and has more than 3,000 employees in 30 countries worldwide. Dr. Leonid Ber, COO, stated, ''We are pleased to have received the confidence expressed by such a large reputable international accounting firm.'' Mazars and Guerard has commenced an audit of the Company for the fiscal year ending August 31, 1997. A report of the audit should be made available to shareholders within 60 days. ''Safe Harbor'' Statement under the Private Securities Litigation Reform Act of 1995. The statements which are not facts contained in the release are forward-looking statements that involve risks and uncertainties, some of which are outside the Company's control, and accordingly, actual results may differ materially. Factors that might cause such a difference include, but are not limited to, implementation of the Company's strategies, the impact of competitive and industry developments, the results of research and development efforts by the Company, product development by the Company and customer acceptance of the Company's products and services. ImmuDyne is a Texas based company specializing in macrophage technology and immune systems stimulants for cosmetic, human nutritional and aquacultural use. The common stock of ImmuDyne is traded on the OTC Bulletin Board under the symbol IMMD. For investment information, contact the Company at 713/783-7034. Contact: ImmuDyne Inc., Houston 713/783-7034